Lameness Repair Company

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Tuesday, 10-17-2017

PRESS RELEASE

 

PetVivo HOldings Provides Shareholder Update

 

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to provide an update to our shareholders.

 

Information and skilled execution has always led the way to success. It is important to us, the management team of your company, be committed to informing all shareholders of the progress that has been made and is currently underway. Several major steps forward have been taken in the last few months, and there is potentially more to come in the next few.

 

First, I will address the management changes and additions. I accepted the position of CEO and Board Member in June. At the end of August, Cynthia Jenkins joined the company as CFO. The month of September saw the addition of David Deming and Peter Vezmar to the Board of Directors. October solidified the addition of Robin Young and Michael Haider to the Advisory Board. All of the business biographies of these individuals are posted on our website (www.petvivo.com) .

 

Second, as a reporting company, PetVivo has continued the effort to catch up on delinquent filings. It is projected that the final filing to bring the company current with the Securities and Exchange Commission will be submitted in early November. Once current our financial results will be available at most financial web portals that provide financial data.

 

PetVivo has a new home that is in final construction in Edina, Minnesota. Corporate offices, Research and Commercial production facilities will be ready for full operation on December 1st. The first commercial runs of “Kush” will be supporting the sales and marketing roll out scheduled to commence at the same time. We are currently assembling the sales and distribution team that will introduce our first product.

 

Financial support for these activities comes from the completion and oversold round of $525,000 of financing, which ended only last week. The funding is expected to complete the construction and fund the early stages of market and sales.

 

The stock (PETV) has experienced considerable appreciation over the last six months as confidence by investors has grown with the company achieving specific benchmarks. The practice of goal setting, short term and long term has become the norm among the management of your company. We continue to push forward each and every day to make out products a primary component in the canine, equine and eventually human solutions for the future.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

 

 

 

 

 

 

 

 

 

 

Press Release PetVivo Expands Advisory Board With Stem Cell and Orthopedics Experts

Press Release PetVivo Expands Advisory Board With Stem Cell and Orthopedics Experts
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

Created:
Monday, 10-09-2017
PRESS RELEASE

PETVIVO ADDS ROBIN YOUNG AND MICHAEL HAIDER TO ADVISORY BOARD

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce that Robin R. Young and Michael P. Haider have joined the Company’s Advisory Board.

Mr. Young is currently Chief Executive Officer of RRY Publications LLC and PearlDiver Technologies, Inc. RRY Publications is the publisher of Orthopedics This Week and organizer of educational seminars on such topics as Stem Cell Therapies, Clinical Research Issues and New Healthcare Technologies. RRY Publications reaches approximately 200,000 healthcare professionals monthly. PearlDiver is a data mining company which is used by both academic and corporate researchers to conduct research. PearlDiver has been cited in more than 75 peer reviewed journal studies. Previously, Mr. Young spent twenty-five years as a medical technology analyst with such firms as Piper Jaffray, Stephens, Inc. and HealthPoint Capital.

Mr. Young has been a podium speaker at the Foundation for Orthopedic Research, International Society for Advancement Spine Surgery, Laser Spine Institute, Johnson & Johnson Global R&D Congress, The Vatican and the Cedars Sinai Surgeon Conference. His subject topics have included Spine Surgery, Future of Orthopedics, Stem Cells, Regenerative Medicine and Allograft Surgical Products to name a few.

“PetVivo’s developing portfolio of advance biologic therapies is very exciting. I’m looking forward to contributing to the company’s development and success. The pace of medical innovation is accelerating and companies like PetVivo play a critical role in moving these important new technologies from the lab to the practitioner.”

Mr. Haider has over 40 years of medical business, finance and management experience, currently serving as the Co-Founder and CEO of CytoMedical Design Group LLC, a blood based stem cell research company. He previously served as the President and CEO of BioE LLC and BioE, Inc; President/Owner of Kodiak Restoration, a dental and medical equipment service company; Co-founder and President of PulseTrend, Inc., an ambulatory blood pressure device manufacturer; and as Vice President and Chief Financial Officer of PPT Vision, a producer of machine vision technologies. Prior to these endeavors, Mr. Haider held a variety of corporate finance positions at Medtronic, Inc., a leading provider of medical devices.

Mr. Haider and the companies he has led have been named one of the Twin Cities-based Finance and Commerce’s “Innovators of The Year”, received the Minnesota Tekne Award in the Emerging Biotechnology category and a Twin Cities Business, Biosciences Success Story. Since 2009, he has served as a member of National Marrow Foundation (“Be the Match”), New Technology Council and for the past decade he has been an annual presenter of stem cell business strategies to the University of Minnesota School of Pharmacy.

“I am pleased for the opportunity to contribute my business and technical experience to help the commercial success of PetVivo’s exciting technologies and new Kush product line. I am looking forward to working with the terrific team Wes and John are putting together, stated Mr. Haider.

“I have known Robin Young for over three generations. During that time, I have always been fascinated with his achievements. I am looking forward to his continued support and contributions. Mike Haider and I ran into each other quite by accident several years ago in London, England. It was only after conversing a while did we discover that we were both from Minnesota. Mike and Robin have decades of experience in regenerative medicine, more specifically stem cells. It is a privilege to have them working with us,” Said PetVivo’s CEO, Wes Hayne.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

FMW Media Works Corp.’s “New To The Street” Business TV On October 26, 2017, Films Exciting New Line-up – PetVivo Holdings, Inc (PETV), Premier Biomedical, Inc. (BIEI) and Strikeforce Technologies, Inc.(SFOR)

FMW Media Works Corp.’s “New To The Street” Business TV On October 26, 2017, Films Exciting New Line-up – PetVivo Holdings, Inc (PETV), Premier Biomedical, Inc. (BIEI) and Strikeforce Technologies, Inc.(SFOR)

 

GlobeNewswireOctober 3, 2017

NEW YORK, Oct. 03, 2017 (GLOBE NEWSWIRE) — “New To The Street,” a business television show, announces the addition of three exciting new clients to its list of profiled companies, PetVivo Holdings Inc. (PETV), Premier Biomedical, Inc. (BIEI), and Strikeforce Technologies, Inc. (SFOR); filming at show’s NYC broadcasting studios, Thursday, October 26, 2017.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/56f7f35b-3cf1-4308-b11b-2c61de050a7e

Mr. John Lai, President, PetVivo Holdings Inc., a company which developed an exciting technology to combat osteoarthritis in the canine and equine population. John plans to discuss PetVivo Holdings, Inc.’s technology, strategy and mission to deliver treatment for osteoarthritis, improving the lives of the many four- legged friends that families love.

Mr. Lai states, “I’m looking forward to discuss on ‘New To The Street’ how PetVivo’s disruptive technology can revolutionize the treatment and care of osteoarthritis in dogs and horses.  And, I’m excited for PETV to launch commercially its ‘Kush’ product and enter a $3 Billion plus market with this innovative technology.”

Also in the studio, William A Hartman, CEO of Premier Biomedical Inc. to discuss the company’s fight against pain with their phytocannabinoids products. He plans to discuss their recently launched website www.painreliefmeds.com, and how people with pain can find out about their phytocannabinoids products and find relief.

With the recent increases in cyber “hackings,” Mark Kay, CEO of Strikeforce Technologies, Inc. discusses his company’s place in the fight against cyber theft and data breaches. Strikeforce’s designed a suite of services to provide anonymity of your personal and financial information – ProtectID, GuardedID, and Mobiletrust products protect against thieves and hackers with the intent to steal personal information.

Viewers, please look out for the entire guest line-up the week of October 26, 2017. See which Companies profiled on “New To The Street’s” December Broadcast on Fox Business Network TV.  Watch for more news on show’s guests, Agritek Holdings, Inc. (AGTK), Financial Gravity (FGCO), DIBcoin cryptocurrency, Vystar Corp.(OTCPINK:VYST), Genoil, Inc.(GNOLF), MoneyOnMobile, Inc. (MOMT) and Kimberly Parry Organics Company (KPOC).

FMW Media Works Corp. (“New To The Street“) is a leading provider of business profiles and special corporate programming. FMW Media Works produces “New To The Street” which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. “New To The Street” airs as paid TV programming and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations- www.NewToTheStreet.com.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. This press release should be considered in light of all filings of the Company that is contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Contact Information:

For “NEW TO THE STREET”
Adam Becker
(631) 465-0284
Adam.becker@newtothestreet.com

PetVivo Holdings
Wes Hayne, CEO
(612) 296-7305
info@petvivo.com
www.petvivo.com

Premier Biomedical Inc.
William A Hartman, CEO
(724) 633-7033
w.hartman@premierbiomedical.com
premierbiomedical.com

 

 

Real Time Web Analytics